Pluronic® block copolymers for overcoming drug resistance in cancer

Advanced Drug Delivery Reviews

Volumn 54, Issue 5, 2002, Pages 759-779

  Kabanov, Alexander V ^a   Batrakova, Elena V ^a   Alakhov, Valery Yu ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Supratek Pharma Inc   (Canada)

Author keywords

Anthracyclines; Block copolymer; Cancer; MDR; MRP; Multidrug resistant protein; P glycoprotein

Indexed keywords

CELLS; DETOXIFICATION; DRUG PRODUCTS; DRUG THERAPY; TUMORS;

DRUG RESISTANT TUMORS;

COPOLYMERS;

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; METHOTREXATE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; POLOXAMER; SP 1049C; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; ADENOSINE TRIPHOSPHATE; DOXORUBICIN; DRUG CARRIER;

ALOPECIA; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOPLASM VESICLE; DETOXIFICATION; DOSE RESPONSE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; LETHARGY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; MEMBRANE FLUIDITY; METABOLISM; NEOPLASM; ULTRASTRUCTURE;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE FLUIDITY; NEOPLASMS; P-GLYCOPROTEIN; POLOXAMER;

EID: 0037072478     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00047-9     Document Type: Review

References (120)

1. Naito S., Yokomizo A., Koga H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int. J. Urol. 6:1999;427-439.
2. Kröger N., Achterrath W., Hegewisch-Becker S., Mross K., Zander A.R. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat. Rev. 25:1999;279-291.
3. Marie J.P., Legrand O. MDR1/PGP expression as a prognostic factor in acute leukemias. Adv. Exp. Med. Biol. 457:1999;1-9.
4. Kaye S.B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr. Opin. Oncol. Suppl. 1:1998;S15-S19.
5. Pusztai L., Esteva F.J., Cristofanilli M., Hung M.C., Hortobagyi G.N. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat. Rev. 25:1999;271-277.
6. Dalton W.S., Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin. Oncol. 26:1999;23-27.
7. Gianni L. Anthracycline resistance: the problem and its current definition. Semin. Oncol. 4:(Suppl. 10):1997;11-17.
8. Ferry D.R. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int. J. Clin. Pharmacol. Ther. 36:1998;29-40.
9. Krishan A., Fitz C.M., Andritsch I. Drug retention, efflux, and resistance in tumor cells. Cytometry. 29:1997;279-285.
10. van Veen H.W., Konings W.N. Multidrug transport from bacteria to man: similarities in structure and function. Semin. Cancer Biol. 8:1997;183-191.
11. Zaman G.J., et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA. 92:1995;7690-7694.
12. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:1995;445-600.
13. Altan N., Chen Y., Schindler M., Simon S.M. Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med. 187:1998;1583-1598.
14. +-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein. Int. J. Oncol. 12:1998;711-715.
15. Kopecek J., Kopeckova P., Minko T., Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:2000;61-81.
16. Kopecek J., Kopeckova P., Minko T., Lu Z.R., Peterson C.M. Water soluble polymers in tumor targeted delivery. J. Control. Release. 74:2001;147-158.
17. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release. 54:1998;223-233.
18. Minko T., Kopeckova P., Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release. 59:1999;133-148.
19. Tijerina M., Fowers K.D., Kopeckova P., Kopecek J. Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials. 21:2000;2203-2210.
20. Omelyanenko V., Kopeckova P., Gentry C., Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release. 53:1998;25-37.
21. Minko T., Kopeckova P., Kopecek J. Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control. Release. 71:2001;227-237.
22. Batrakova E.V., et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer. 74:1996;1545-1552.
23. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 7:1996;209-216.
24. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56:1996;3626-3629.
25. Ranson M., Ferry D., Kerr D., Radford J., Dickens D., Alakhov V., Brampton M., Margison J. Results of a Cancer Research Campaign phase I dose escalation trial of SP1049C in patients with advanced cancer. 5th International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice. 2002;15 The Welsh School of Pharmacy, Cardiff University, Cardiff.
26. Mansouri A., Henle K.J., Nagle W.A. Multidrug resistance: prospects for clinical management. SAAS Bull. Biochem. Biotechnol. 5:1992;48-52.
27. Ouar Z., Lacave R., Bens M., Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells. Cell Biol. Toxicol. 15:1999;91-100.
28. Beck W.T., Danks M.K. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin. Cancer Biol. 2:1991;235-244.
29. Bertino J.R., Goker E., Gorlick R., Li W.W., Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells. 14:1996;5-9.
30. Takemura Y., Kobayashi H., Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. Int. J. Hematol. 66:1999;459-477.
31. Goldstein L.J., Gottesman M.M., Pastan I. Multidrug resistance in human cancers. Crit. Rev. Oncol. Hematol. 12:1992;243-253.
32. Kuwano M., Toh S., Uchiumi T., Takano H., Kohno K., Wada M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des. 14:1999;123-131.
33. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357.
34. Lum B.L., Gosland M.P., Kaubisch S., Sikic B.I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy. 13:1993;88-109.
35. van Aubel R.A., Koenderink J.B., Peters J.G., van Os C.H., Russel F.G. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol. Pharmacol. 56:1999;714-719.
36. Twentyman P.R. Transport proteins in drug resistance: biology and approaches to circumvention. J. Intern. Med. Suppl. 740:1997;133-137.
37. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55:1995;5342-5347.
38. Nooter K., Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192:1996;768-780.
39. Cleary I., Doherty G., Moran E., Clynes M. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 53:1997;1493-1502.
40. Shapiro A.B., Fox K., Lee P., Yang Y.D., Ling V. Functional intracellular P-glycoprotein. Int. J. Cancer. 76:1998;857-864.
41. Moriyama Y. Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. J. Exp. Biol. 199:1996;1447-1454.
42. Benderra Z., Morjani H., Trussardi A., Manfait M. Evidence for functional discrimination between leukemic cells overexpressing multidrug-resistance associated protein and P-glycoprotein. Adv. Exp. Med. Biol. 457:1999;151-160.
43. Gamcsik M.P., Dolan M.E., Andersson B.S., Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharm. Des. 5:1999;587-605.
44. Calvert P., Yao K.S., Hamilton T.C., O'Dwyer P.J. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 111-112:1998;213-224.
45. Nielsen D., Maare C., Skovsgaard T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27:1996;251-255.
46. Salinas A.E., Wong M.G. Glutathione S-transferases - a review. Curr. Med. Chem. 6:1999;279-309.
47. Schecter R.L., Alaoui-Jamali M.A., Batist G. Glutathione S-transferase in chemotherapy resistance and in carcinogenesis. Biochem. Cell. Biol. 70:1992;349-353.
48. Chresta C.M., Arriola E.L., Hickman J.A. Apoptosis and cancer chemotherapy. Behring. Inst. Mitt. 97:1996;232-240.
49. Au J.L., Panchal N., Li D., Gan Y. Apoptosis: a new pharmacodynamic endpoint. Pharm. Res. 14:1997;1659-1671.
50. Gerson S.L., Willson J.K. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol. Oncol. Clin. North Am. 9:1995;431-450.
51. Erickson L.C. The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. Semin. Cancer Biol. 2:1991;257-265.
52. Gjertsen B.T., Logothetis C.J., McDonnell T.J. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev. 17:1999;345-351.
53. Haq R., Zanke B. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev. 17:1998;233-239.
54. Smyth M.J., Kraskovskis E., Sutton V.R. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 95:1998;7024-7029.
55. Robinson L.J., Roberts W.K., Ling T.T., Lamming D., Sternberg S.S., Roepe P.D. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry. 36:1997;11169-11178.
56. Bezombes C., Maestre N., Laurent G., Levade T., Bettaieb A., Jaffrezou J.P. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J. 12:1998;101-109.
57. Johnstone R.W., Cretney E., Smyth M.J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 93:1999;1075-1085.
58. Schmolka I.R. A review of block polymer surfactants. J. Am. Oil Chem. Soc. 54:1977;110-116.
59. Nagarajan R. Solubilization of hydrocarbons and resulting aggregate shape transitions in aqueous solutions of Pluronic (PEO-PPO-PEO) block copolymers. Coll. Surf. B: Biointerfaces. 16:1999;55-72.
60. Kabanov A.V., Nazarova I.R., Astafieva I.V., Batrakova E.V., Alakhov V.Y., Yaroslavov A.A., Kabanov V.A. Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b-oxyethylene) solutions. Macromolecules. 28:1995;2303-2314.
61. Batrakova E.V., Han H.Y., Miller D.W., Kabanov A.V. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15:1998;1525-1532.
62. Alakhov V.Y., Kabanov A.V. Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Exp. Opin. Invest. Drugs. 7:1998;1453-1473.
63. Batrakova E.V., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1999;1373-1379.
64. Alexandridis P., Athanassiou V., Fukuda S., Hatton T.A. Surface activity of poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide) copolymers. Langmuir. 10:1994;2604-2612.
65. Alexandridis P., Holzwarth J.F., Hatton T.A. Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: thermodynamics of copolymer association. Macromolecules. 27:1994;2414-2425.
66. Hurter P.N., Scheutjens J.M.H.M., Hatton T.A. Molecular modeling of micelle formation and solubilization in block copolymer micelles. 1. A self-consistent mean-field lattice theory. Macromolecules. 26:1993;5592-5601.
67. Hurter P.N., Scheutjens J.M.H.M., Hatton T.A. Molecular modeling of micelle formation and solubilization in block copolymer micelles. 2. Lattice theory for monomers with internal degrees of freedom. Macromolecules. 26:1993;5030-5040.
68. Page M., Alakhov V.Y. Elimination of P-gp-mediated multidrug resistance by solubilization in Pluronic micelles. Proceedings of the Annual Meeting of the American Association for Cancer Research. Vol. 33:1992;A3302.
69. Alakhov V., Klinski E., Li S., Pietrzynski G., Venne A., Batrakova E., Bronitch T., Kabanov A.V. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B: Biointerfaces. 16:1999;113-134.
70. Woodcock D.M., Jefferson S., Linsenmeyer M.E., Crowther P.J., Chojnowski G.M., Williams B., Bertoncello I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:1990;4199-4203.
71. Woodcock D.M., Linsenmeyer M.E., Chojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66:1992;62-68.
72. Webster L., Linsenmeyer M., Millward M., Morton C., Bishop J., Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst. 85:1993;1685-1690.
73. Coon J.S., Knudson W., Clodfelter K., Lu B., Weinstein R.S. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 51:1991;897-902.
74. Dudeja P.K., Anderson K.M., Harris J.S., Buckingham L., Coon J.S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319:1995;309-315.
75. Buckingham L.E., Balasubramanian M., Emanuele R.M., Clodfelter K.E., Coon J.S. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int. J. Cancer. 62:1995;436-442.
76. Buckingham L.E., Balasubramanian M., Safa A.R., Shah H., Komarov P., Emanuele R.M., Coon J.S. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters. Int. J. Cancer. 65:1996;74-79.
77. Komarov P.G., Shtil A.A., Buckingham L.E., Balasubramanian M., Piraner O., Emanuele R.M., Roninson I.B., Coon J.S. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int. J. Cancer. 68:1996;245-250.
78. Zordan-Nudo T., Ling V., Liu Z., Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. 53:1993;5994-6000.
79. Evers R., Kool M., Smith A.J., van Deemter L., de Haas M., Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer. 83:2000;366-374.
80. Batrakova E.V., Miller D.W., Li S., Alakhov V.Y., Kabanov A.V., Elmquist W.F. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296:2001;551-557.
81. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V., Kabanov A.V. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 8:1997;649-657.
82. Batrakova E.V., Han H.Y., Alakhov V., Miller D.W., Kabanov A.V. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15:1998;850-855.
83. Miller D.W., Batrakova E.V., Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm. Res. 16:1999;396-401.
84. Draper M.P., Martell R.L., Levy S.B. Active efflux of the free acid form of the fluorescent dye 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Eur. J. Biochem. 243:1997;219-224.
85. Bagrij T., Klokouzas A., Hladky S.B., Barrand M.A. Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem. Pharmacol. 62:2001;199-206.
86. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer. 92:2001;777-783.
87. Priebe W., Krawczyk M., Kuo M.T., Yamane Y., Savaraj N., Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. 247:1998;859-863.
88. Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer. 83:2000;375-383.
89. Batrakova E.V., Li S., Alakhov V.Y., Kabanov A.V. Selective energy depletion and sensitization of multiple drug resistant cancer cells by Pluronic block copolymers. Polym. Prepr. 41:2000;1639-1640.
90. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer. 85:2001;1987-1997.
91. 32P]ATP. Biochem. Int. 26:1992;587-595.
92. Chiu P., Karler R., Craven C., Olsen D.M., Turkanis S.A. The influence of delta9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption. Res. Commun. Chem. Pathol. Pharmacol. 12:1975;267-286.
93. Kirillova G.P., Mokhova E.N., Dedukhova V.I., Tarakanova A.N., Ivanova V.P., Efremova N.V., Topchieva I.N. The influence of pluronics and their conjugates with proteins on the rate of oxygen consumption by liver mitochondria and thymus lymphocytes. Biotechnol. Appl. Biochem. 18:1993;329-339.
94. Rapoport N., Marin A.P., Timoshin A.A. Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch. Biochem. Biophys. 384:2000;100-108.
95. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on p-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:2001;483-493.
96. van Zutphen H., Merola A.J., Brierley G.P., Cornwell D.G. The interaction of nonionic detergents with lipid bilayer membranes. Arch. Biochem. Biophys. 152:1972;755-766.
97. Atkinson T.P., Smith T.F., Hunter R.L. Histamine release from human basophils by synthetic block co-polymers composed of polyoxyethylene and polyoxypropylene and synergy with immunologic and non-immunologic stimuli. J. Immunol. 141:1988;1307-1310.
98. Atkinson T.P., Smith T.F., Hunter R.L. In vitro release of histamine from murine mast cells by block co-polymers composed of polyoxyethylene and polyoxypropylene. J. Immunol. 141:1988;1302-1306.
99. + uptake by non-ionic detergents. Arch. Biochem. Biophys. 152:1972;744-754.
100. Brustovetskii N.N., Dedukhova V.N., Egorova M.V., Mokhova E.N., Skulachev V.P. Uncoupling of oxidative phosphorylation by fatty acids and detergents suppressed by ATP/ADP antiporter inhibitors. Biochemistry (Mosc.). 56:1991;1042-1048.
101. Kaplan O., Jaroszewski J.W., Clarke R., Fairchild C.R., Schoenlein P., Goldenberg S., Gottesman M.M., Cohen J.S. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res. 51:1991;1638-1644.
102. Kaplan O., Navon G., Lyon R.C., Faustino P.J., Straka E.J., Cohen J.S. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 50:1990;544-551.
103. Marton A., Mihalik R., Bratincsak A., Adleff V., Petak I., Vegh M., Bauer P.I., Krajcsi P. Apoptotic cell death induced by inhibitors of energy conservation: Bcl-2 inhibits apoptosis downstream of a fall of ATP level. Eur. J. Biochem. 250:1997;467-475.
104. Martin D.S., Stolfi R.L., Colofiore J.R., Nord L.D., Sternberg S. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest. 12:1994;296-307.
105. Melik-Nubarov N.S., Pomaz O.O., Dorodnych T., Badun G.A., Ksenofontov A.L., Schemchukova O.B., Arzhakov S.A. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers. FEBS Lett. 446:1999;194-198.
106. Regev R., Assaraf Y.G., Eytan G.D. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. 259:1999;18-24.
107. Druekes P., Schinzel R., Palm D. Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal. Biochem. 230:1995;173-177.
108. Shepard R.L., Winter M.A., Hsaio S.C., Pearce H.L., Beck W.T., Dantzig A.H. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem. Pharmacol. 56:1998;719-727.
109. Rebbeor J.F., Senior A.E. Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochim. Biophys. Acta. 1369:1998;85-93.
110. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
111. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry. 37:1998;5010-5019.
112. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
113. Nerurkar M.M., Ho N.F., Burton P.S., Vidmar T.J., Borchardt R.T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:1997;813-821.
114. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40:(Suppl.):1997;S13-S19.
115. Sakamoto H., Hara H., Hirano K., Adachi T. Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Cancer Lett. 135:1999;113-119.
116. Kitchens M.E., Forsthoefel A.M., Barbour K.W., Spencer H.T., Berger F.G. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. Mol. Pharmacol. 56:1999;1063-1070.
117. Hooijberg J.H., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
118. Chen G., Waxman D.J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol. 49:1995;1691-1701.
119. Cai Y., Wu M.H., Ludeman S.M., Rdina D.J., Dolan M.E. Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res. 59:1999;3059-3063.
120. Lee F.Y., Sciandra J., Siemann D.W. A study of the mechanism of resistance to adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport. Biochem. Pharmacol. 38:1989;3697-3705.